ALAUNOS THERAPEUTICS
Alaunos Therapeutics is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.
ALAUNOS THERAPEUTICS
Industry:
Biotechnology Genetics Oncology Pharmaceutical Therapeutics
Founded:
2005-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.alaunos.com
Total Employee:
11+
Status:
Active
Contact:
617-259-1970
Email Addresses:
[email protected]
Total Funding:
293.39 M USD
Technology used in webpage:
Domain Not Resolving Amazon Font Awesome IPv6 Microsoft COVID-19 CPanel SSL Akamai Hosted Comcast Starfield Technologies
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Boston Pharmaceuticals
Boston Pharmaceuticals Provides Healthcare Services.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Medeor Therapeutics
Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Henderson Global Investors
Henderson Global Investors investment in Post-IPO Equity - Alaunos Therapeutics
Essex Woodlands Healthcare Partners
Essex Woodlands Healthcare Partners investment in Post-IPO Equity - Alaunos Therapeutics
ProQuest Investments
ProQuest Investments investment in Post-IPO Equity - Alaunos Therapeutics
Pinto Technology Ventures
Pinto Technology Ventures investment in Post-IPO Equity - Alaunos Therapeutics
LBI Group
LBI Group investment in Post-IPO Equity - Alaunos Therapeutics
ProQuest Investments
ProQuest Investments investment in Post-IPO Equity - Alaunos Therapeutics
Pangaea Asset Management
Pangaea Asset Management investment in Post-IPO Equity - Alaunos Therapeutics
Paramount BioCapital Asset Management
Paramount BioCapital Asset Management investment in Post-IPO Equity - Alaunos Therapeutics
LBI Group
LBI Group investment in Post-IPO Equity - Alaunos Therapeutics
Cycad Group
Cycad Group investment in Post-IPO Equity - Alaunos Therapeutics
Key Employee Changes
Official Site Inspections
http://www.alaunos.com Semrush global rank: 11.26 M Semrush visits lastest month: 170
- Host name: 161.0.153.160.host.secureserver.net
- IP address: 160.153.0.161
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Alaunos Therapeutics"
Investors | Alaunos
Apr 4, 2023 Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty …See details»
IR Landing Page - Alaunos
Leveraging its multi-platform approach, Alaunos is at the forefront of immuno-oncology. Press Releases. Nov 09, 2021 Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of …See details»
BOARD OF DIRECTORS - Alaunos
Dr. Hofmeister has over 25 years of scientific leadership and a successful track record of drug discovery and early development. Since March 2022, he holds the CSO position at a stealth …See details»
Alaunos Therapeutics - LinkedIn
Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we ...See details»
Alaunos Therapeutics - Crunchbase Company Profile & Funding
Alaunos Therapeutics is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology …See details»
Corporate Governance - Alaunos
The board of directors of Alaunos (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound …See details»
Alaunos Therapeutics Company Profile 2024: Stock ... - PitchBook
Alaunos Therapeutics’s EPS for 12 months was -$315.39. Data Transparency. Meet our data hygiene team. Discover how our experts ensure you’re getting the most accurate financial data …See details»
Alaunos Therapeutics - Overview, News & Similar companies
May 20, 2024 Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting HOUSTON, May 25, 2023 …See details»
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 ...
Mar 30, 2022 Alaunos will host a conference call and webcast today, March 30, 2022 at 8:30am ET. Participants should dial 844-309-0618 (United States) or 661-378-9465 (International) with …See details»
Alaunos Therapeutics - Contacts, Employees, Board Members, …
Organization. Alaunos Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Contacts 39. About. Alaunos Therapeutics …See details»
OUR SCIENCE - Alaunos
Alaunos’ hunTR ® (hu man n eoantigen T-cell R eceptor) platform enables the rapid identification of new, wholly owned TCRs to further expand the Company’s growing TCR library. hunTR ® is …See details»
Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance
Find the latest Alaunos Therapeutics, Inc. (TCRT) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 ...
Feb 28, 2023 Alaunos Therapeutics is a leader in the science of T-cell receptor (TCR) cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage …See details»
Alaunos Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
NSCLC includes but is not limited to squamous cell carcinoma, adenosquamous carcinoma or adenocarcinomas Cholangiocarcinoma Subjects' somatic mutation(s) and HLA type restriction …See details»
Ziopharm Oncology Highlights Operational Progress & Rebrands …
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral . Sleeping Beauty. gene transfer …See details»
Ziopharm Oncology Changes Name to Alaunos, Begins Enrolling T …
Jan 26, 2022 Alaunos employees are staffing the fully operational facility. Alaunos has also begun enrolling patients with various solid cancer types within the Phase I/II TCR-T clinical …See details»
Alaunos: Taking Autologous T-Cell Receptor Therapies To The …
Aug 31, 2022 Alaunos Therapeutics, Inc. (NASDAQ:TCRT) is a great speculative biotech play to look into. The reason why I state that is because it is developing autologous T-cell receptor …See details»
OUR APPROACH - Alaunos
Alaunos’ Clinical TCR Library targets the most frequent mutations in KRAS, TP53 and EGFR which are prevalent in gastrointestinal (colon, bile duct, pancreas), lung, and gynecological …See details»
Manager/Director, Clinical Operations - Alaunos
Inquiries and Resumes should be sent to: [email protected] About Alaunos Alaunos is developing commercially scalable, cost-effective T-cell receptor (TCR) T-cell therapies based …See details»